Coston, Mc Isaac & Partners Pyxis Oncology, Inc. Transaction History
Coston, Mc Isaac & Partners
- $281 Million
- Q4 2024
A detailed history of Coston, Mc Isaac & Partners transactions in Pyxis Oncology, Inc. stock. As of the latest transaction made, Coston, Mc Isaac & Partners holds 30 shares of PYXS stock, worth $42. This represents 0.0% of its overall portfolio holdings.
Number of Shares
30
Previous 30
-0.0%
Holding current value
$42
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding PYXS
# of Institutions
104Shares Held
28.2MCall Options Held
658KPut Options Held
54.1K-
Deep Track Capital, LP Greenwich, CT4.18MShares$5.86 Million0.57% of portfolio
-
Laurion Capital Management LP New York, NY3.63MShares$5.08 Million0.18% of portfolio
-
Black Rock Inc. New York, NY2.79MShares$3.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.43MShares$3.41 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.91MShares$2.67 Million0.0% of portfolio
About Pyxis Oncology, Inc.
- Ticker PYXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,096,400
- Market Cap $49.1M
- Description
- Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...